Insight
New Research from MD Anderson Shows that Teclistamab is Safe and Effective for Older Patients with RRMM
mdanderson.org

New Research from MD Anderson Shows that Teclistamab is Safe and Effective for Older Patients with RRMM

MD Anderson Cancer Center shared a post on LinkedIn:

“New research from MD Anderson shows that teclistamab, a bispecific antibody, is safe and effective for older patients with relapsed/refractory multiple myeloma. In a study led by our Dr. Oren Pasvolsky and Dr. Hans Lee, patients ages 75 and older experienced similar safety and better progression-free survival compared to younger patients. These findings may help expand access to this promising therapy for older adults.”

Read further.

More posts featuring MD Anderson Cancer Center.

cancer Hans Lee MD Anderson Cancer Center MM multiple myeloma OncoDaily Oncology Oren Pasvolsky RRMM teclistamab